Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Study of BBI503 Monotherapy in Patients With Advanced Solid Tumors, or BBI503 Plus Sorafenib Combination Therapy in Patients With Advanced Hepatocellular Carcinoma

NCT02354898 is registered in ClinicalTrials.gov with Sumitomo Pharma Co., Ltd. as lead sponsor.

NCT NCT02354898
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02354898 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Study of BBI503 Monotherapy in Patients With Advanced Solid Tumors, or BBI503 Plus Sorafenib Combination Therapy in Patients With Advanced Hepatocellular Carcinoma
Lead sponsor
Sumitomo Pharma Co., Ltd.
Phase
Phase 1
Overall status
Completed
Start date
March 31, 2015
Completion date
October 31, 2018
Enrollment
60 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumors, hepatocellular carcinoma